JPRN-UMIN000006912招募中未知
A Randomized Phase II Trial of Pemetrexed or Pemetrexed/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer - A randomized phase II trial of pemetrexed or pemetrexed/bevacizumab in elderly NSCLC patients
Hokuriku Thoracic Oncology Group0 个研究点目标入组 60 人开始时间: 2012年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
patients are recruiting.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Interstitial pneumonia or pulmonary fibrosis on chest X-ray 2) brain metastasis 3) history of hemoptysis 4) history or complications of obvious diverticulitis 5) cavitary lesions 1cm or more 6) serious complications 7) pleural effusion, ascitis drainage is necessary for, and pericardial effusion 8) active multiple primary cancer 9) pregnancy, lactation, or, intention to pregnancy 10) a history of serious drug hypersensitivity 11) patients whom it is judged to have difficulty in participation in study because of psychosis or neurologic disease 12) The case that is judged to be inadequacy for this study
研究者
相似试验
已完成
2 期
Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00269152Eli Lilly and Company122
已完成
2 期
A Trial for Patients With Advanced/Recurrent Endometrial CancerNeoplasmsNeoplasms by SiteUrogenital NeoplasmsGenital Neoplasms, FemaleUterine NeoplasmsEndometrial NeoplasmsCancer of EndometriumEndometrial CancerCancer of the EndometriumEndometrium CancerNeoplasms, EndometrialNCT00377520Eli Lilly and Company27
已完成
2 期
Trial of Poor Performance Status Patients (ToPPS)Non Small Cell Lung CancerNCT00892710SCRI Development Innovations, LLC172
已完成
2 期
Pemetrexed in Patients With Soft Tissue SarcomaSarcomaNCT00427466University Hospital Tuebingen54
已完成
2 期
Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small-Cell Lung CancerNCT00402051Eli Lilly and Company133